RO5466731 + RO5190591 + ritonavir + ribavirin

This is a **four-drug oral antiviral combination regimen** comprised of RO5466731, RO5190591, ritonavir, and ribavirin, studied for the treatment of **chronic hepatitis C virus (HCV) infection genotype 1**. - **RO5466731** is a direct-acting antiviral, likely a non-nucleoside HCV polymerase inhibitor, developed by Roche. - **RO5190591** (danoprevir) is a protease inhibitor targeting the HCV NS3/4A protease. - **Ritonavir** acts as a pharmacokinetic enhancer (booster) of danoprevir by inhibiting CYP3A-mediated metabolism. - **Ribavirin** is a nucleoside analogue with broad-spectrum antiviral activity, often used as part of combination therapy for HCV to improve virologic responses but not effective as monotherapy. This combination was evaluated in a phase II, multicenter, open-label study (ANNAPURNA, NCT01628094) sponsored by Hoffmann-La Roche for efficacy and safety in both treatment-naïve and interferon-null responder patients with chronic HCV[1][3][5].

Other names

ritonavirribavirin